Es ist bekannt, Lösungen für Körperinfusionen mit geeigneten Ionen und Nährstoffen zu versehen. Sokönnen derartige Lösungen im einfacheren Fall einen Gehalt von 0,9% NaCl besitzen; sie können aber aucheine Vielzahl von Ionen, Glukose, Serum-Eiweiß sowie weitere Blutbestandteile gelöst enthalten. ÄhnlicheLösungen verwendet man zur in-vitro-Behandlung von überlebendem Gewebe, z. B. für Zellkulturen oder zurKonservierung von vitalen Organen. In sämtlichen Fällen dient als Lösungsmittel für die zu lösenden Stoffenormales Wasser, manchmal mit geringen Anteilen von Glycerin.It is known to provide solutions for body infusions with suitable ions and nutrients. SoIn the simpler case, such solutions can contain 0.9% NaCl; but they can toocontain a large number of dissolved ions, glucose, serum protein and other blood components. SimilarSolutions are used for the in vitro treatment of surviving tissue, e.g. B. for cell cultures or forPreservation of vital organs. In all cases serves as a solvent for the substances to be dissolvednormal water, sometimes with small amounts of glycerine.
Es wurde nun gefunden, daß derartige Lösungen oder Medien biologische Objekte wie Zellen, Organe und denGesamtorganismus gegen Schädigungen besser konservieren, wenn dem üblichen Lösungsmittel Wasser (H2O)ein Anteil von 2—99,9% schweren Wassers (D2O) zugesetzt wird. Als besonders vorteilhafter Konzentrationsbereichuat sich ein Schwerwasser-Anteil von 7—25% erwiesen. Die Stabilisierung biologischerSysteme nimmt bis zu einem Schwerwasser-Anteil von 10—15% besonders stark zu. Eine weitere Erhöhungder Schwerwasserkonzentration führt zwar zu einer weiteren Erhöhung der biologischen Stabilisierung, derrelative Effekt ist aber geringer.It has now been found that such solutions or media preserve biological objects such as cells, organs and the entire organism better against damage if the usual solvent water (H2 O) contains 2-99.9% heavy water (D2 O). is added. A heavy water content of 7-25% has proven to be a particularly advantageous concentration range. The stabilization of biological systems increases particularly strongly up to a heavy water content of 10-15%. A further increase in the heavy water concentration leads to a further increase in biological stabilization, but the relative effect is less.
Manchmal wird man zweckmäßigerweise den Schwerwasser-Anteil im primären Medium so hochbemessen, daß die Schwerwasserkonzentration nach Verdünnung durch den Wasseranteil im Gewebe wieder7—25% beträgtSometimes the proportion of heavy water in the primary medium is expediently so highmeasured that the heavy water concentration after dilution by the water content in the tissue again7-25%
Die erfindungsgemäß D2O-haltigen Lösungen erlauben die Konservierung der nativen biologischenEigenschaften von Zellen und Organen über einen längeren Zeitraum als im entsprechenden H2O-Medium.Eine spezielle Anwendung ist das Durchströmen von Organen, die zu Transplantationszwecken konserviertwerden sollen. Dabei kann mit der erfindungsgemäßen Lösung, die noch zusätzlich Blutanteile gelöst oder inSuspension enthalten kann, den Organen zusätzlich Sauerstoff zugeführt werden.The D2O-containing solutions according to the invention allow the native biological solutions to be preservedProperties of cells and organs over a longer period of time than in the corresponding H2O medium.A special application is the perfusion of organs that have been preserved for transplantation purposesshould be. Here, with the solution according to the invention, which also dissolved or inCan contain suspension, the organs are additionally supplied with oxygen.
Eine weitere Anwendung ergibt sich bei der Konservierung von Seren, Blutkonserven und Enzymenund ähnlichem biologischem Material, das im Laufe der Zeit oder durch zu hohe oder zu tiefe Temperaturendenaturiert wird. Auch hierbei ist die Effektivität einer D2O-Konzentration im Bereich von 7—25% besondersausgeprägtAnother application is the preservation of serums, blood products and enzymesand similar biological material that changes over time or from temperatures that are too high or too lowis denatured. Here, too, the effectiveness of a D2O concentration in the range of 7-25% is specialpronounced
Die stabilisierenden Effekte von schwerem Wasser bei Erythrocyten beim Erwärmen bzw. beim Gefrierenund bei osmotischer Schädigung gehen aus folgenden Kurven hervor.The stabilizing effects of heavy water on erythrocytes when heated or when frozenand in the case of osmotic damage can be seen from the following curves.
6060
2020th
20 40 U K20 40 U K
Änderung des Schutzeffektes mit der D2O-Konzentrationbei Erythrocyten:Change in the protective effect with the D2 O concentration in erythrocytes:
Obere Kurve: Hämolyse durch Hyperthermie 55° C,40 min, 5%ige Zellsuspension mit 9 g/l NaCl,Upper curve: hemolysis by hyperthermia 55 ° C,40 min, 5% cell suspension with 9 g / l NaCl,
Mittlere Kurve: Hämolyse hypoosmotische Salz-Konzentration (3,8 g/l NaCl), 5%igeZellsuspension 20° C, 20 min,Middle curve: hemolysis hypoosmotic salt concentration (3.8 g / l NaCl), 5%Cell suspension 20 ° C, 20 min,
Untere Kurve: Hämolyse durch Gefrieren -196° C,12 h (Abkühlung -4,3°/min), 5%ige Zellsuspension
55Lower curve: hemolysis by freezing -196 ° C, 12 h (cooling -4.3 ° / min), 5% cell suspension
55
Aus der Kurve ist ersichtlich, daß bei den drei geprüften Schädigungsarten der Schutzeffekt nichtlinear mit der Zunahme der D2O-Konzentration ansteigt, sondern daß bereits bei einer Konzentrationvon ca. 20% D2O 60—75% der maximalen Schutzwirkungerreicht wird.The curve shows that with the three types of damage tested, the protective effect does not increase linearly with the increase in the D2O concentration, but that 60-75% of the maximum protective effect is achievedat a concentration of approx. 20% D 2 O.
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2253086ADE2253086C3 (en) | 1972-10-25 | 1972-10-25 | Preserving solutions for infusion and for storage of tissues and tissue parts |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2253086ADE2253086C3 (en) | 1972-10-25 | 1972-10-25 | Preserving solutions for infusion and for storage of tissues and tissue parts |
| Publication Number | Publication Date |
|---|---|
| DE2253086A1 DE2253086A1 (en) | 1974-05-09 |
| DE2253086B2 DE2253086B2 (en) | 1978-06-15 |
| DE2253086C3true DE2253086C3 (en) | 1979-02-15 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2253086AExpiredDE2253086C3 (en) | 1972-10-25 | 1972-10-25 | Preserving solutions for infusion and for storage of tissues and tissue parts |
| Country | Link |
|---|---|
| DE (1) | DE2253086C3 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662185B2 (en) | 1999-12-30 | 2010-02-16 | Osteotech, Inc. | Intervertebral implants |
| US7726002B2 (en) | 2001-12-05 | 2010-06-01 | Osteotech, Inc. | Processes for making spinal intervertebral implant, interconnections for such implant |
| US7780708B2 (en) | 2000-10-20 | 2010-08-24 | Osteotech, Inc. | Implant retaining device |
| US8202539B2 (en) | 2007-10-19 | 2012-06-19 | Warsaw Orthopedic, Inc. | Demineralized bone matrix compositions and methods |
| US8328876B2 (en) | 2003-12-31 | 2012-12-11 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US8333985B2 (en) | 2004-01-27 | 2012-12-18 | Warsaw Orthopedic, Inc. | Non-glycerol stabilized bone graft |
| US8357384B2 (en) | 2007-06-15 | 2013-01-22 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US8372157B2 (en) | 2007-02-12 | 2013-02-12 | Warsaw Orthopedic, Inc. | Joint revision implant |
| US8642061B2 (en) | 2007-06-15 | 2014-02-04 | Warsaw Orthopedic, Inc. | Method of treating bone tissue |
| US8734525B2 (en) | 2003-12-31 | 2014-05-27 | Warsaw Orthopedic, Inc. | Osteoinductive demineralized cancellous bone |
| US8911759B2 (en) | 2005-11-01 | 2014-12-16 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US9011537B2 (en) | 2009-02-12 | 2015-04-21 | Warsaw Orthopedic, Inc. | Delivery system cartridge |
| US9333082B2 (en) | 2007-07-10 | 2016-05-10 | Warsaw Orthopedic, Inc. | Delivery system attachment |
| US9554920B2 (en) | 2007-06-15 | 2017-01-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions having nanoscale textured surfaces |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2738299A (en)* | 1998-03-10 | 1999-09-27 | Imperial College Of Science, Technology And Medicine | Solution |
| RU2218913C2 (en)* | 2001-01-24 | 2003-12-20 | Государственный научно-исследовательский институт особо чистых биопрепаратов | Interferon preparation |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662185B2 (en) | 1999-12-30 | 2010-02-16 | Osteotech, Inc. | Intervertebral implants |
| US8672980B2 (en) | 2000-10-20 | 2014-03-18 | Warsaw Orthopedic, Inc. | Implant retaining device |
| US7780708B2 (en) | 2000-10-20 | 2010-08-24 | Osteotech, Inc. | Implant retaining device |
| US7726002B2 (en) | 2001-12-05 | 2010-06-01 | Osteotech, Inc. | Processes for making spinal intervertebral implant, interconnections for such implant |
| US9034358B2 (en) | 2003-12-31 | 2015-05-19 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US9415136B2 (en) | 2003-12-31 | 2016-08-16 | Warsaw Orthopedic, Inc. | Osteoinductive demineralized cancellous bone |
| US8328876B2 (en) | 2003-12-31 | 2012-12-11 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US8734525B2 (en) | 2003-12-31 | 2014-05-27 | Warsaw Orthopedic, Inc. | Osteoinductive demineralized cancellous bone |
| US8333985B2 (en) | 2004-01-27 | 2012-12-18 | Warsaw Orthopedic, Inc. | Non-glycerol stabilized bone graft |
| US8911759B2 (en) | 2005-11-01 | 2014-12-16 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US8992965B2 (en) | 2005-11-01 | 2015-03-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US8372157B2 (en) | 2007-02-12 | 2013-02-12 | Warsaw Orthopedic, Inc. | Joint revision implant |
| US8642061B2 (en) | 2007-06-15 | 2014-02-04 | Warsaw Orthopedic, Inc. | Method of treating bone tissue |
| US8357384B2 (en) | 2007-06-15 | 2013-01-22 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US9554920B2 (en) | 2007-06-15 | 2017-01-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions having nanoscale textured surfaces |
| US9333082B2 (en) | 2007-07-10 | 2016-05-10 | Warsaw Orthopedic, Inc. | Delivery system attachment |
| US9358113B2 (en) | 2007-07-10 | 2016-06-07 | Warsaw Orthopedic, Inc. | Delivery system |
| US9492278B2 (en) | 2007-07-10 | 2016-11-15 | Warsaw Orthopedic, Inc. | Delivery system |
| US8435566B2 (en) | 2007-10-19 | 2013-05-07 | Warsaw Orthopedic, Inc. | Demineralized bone matrix compositions and methods |
| US8202539B2 (en) | 2007-10-19 | 2012-06-19 | Warsaw Orthopedic, Inc. | Demineralized bone matrix compositions and methods |
| US9011537B2 (en) | 2009-02-12 | 2015-04-21 | Warsaw Orthopedic, Inc. | Delivery system cartridge |
| US9101475B2 (en) | 2009-02-12 | 2015-08-11 | Warsaw Orthopedic, Inc. | Segmented delivery system |
| US9220598B2 (en) | 2009-02-12 | 2015-12-29 | Warsaw Orthopedic, Inc. | Delivery systems, tools, and methods of use |
| Publication number | Publication date |
|---|---|
| DE2253086B2 (en) | 1978-06-15 |
| DE2253086A1 (en) | 1974-05-09 |
| Publication | Publication Date | Title |
|---|---|---|
| DE2253086C3 (en) | Preserving solutions for infusion and for storage of tissues and tissue parts | |
| Caldwell | Studies on the internal pH of large muscle and nerve fibres | |
| DE69308673T2 (en) | Solution for use in organ transplantation | |
| DE3784916T4 (en) | GLUCOSE-FREE MEDIA FOR THE STORAGE OF BLOOD PLATES. | |
| DE68921945T2 (en) | Method for lyophilizing cells Lyophilizing media and method for restoring lyophilized cells. | |
| CH624579A5 (en) | ||
| DE2655801A1 (en) | METHOD FOR PRODUCING A MASS OF LOADED CELLS SUSPENDED IN A PHYSIOLOGICAL SOLUTION | |
| EP0040799A2 (en) | Stabilized thrombin preparation | |
| DE69811220T2 (en) | COMPOSITIONS FOR THE PRESERVATION OF LIVING BIOLOGICAL MATERIALS AND METHOD FOR THEIR USE | |
| DE4331711C2 (en) | Solution for perfusion, preservation and re-perfusion of organs | |
| Whittembury et al. | Electrical potential difference measurements in perfused single proximal tubules of Necturus kidney | |
| CH657502A5 (en) | METHOD FOR PRODUCING FLEXIBLE, SUSTAINABLY MADE NON-PRESERVED AND PRESERVED BIOLOGICAL MATERIALS. | |
| Hausmann et al. | Iron storage in macrophages and endothelial cells. Histochemistry, ultrastructure, and clinical significance | |
| DE2258519A1 (en) | PROCESS FOR OBTAINING A COSMETOLOGICAL PRODUCT | |
| CN104542571B (en) | A kind of preserving corpse samples liquid | |
| EP0012272B1 (en) | Protecting solution for heart and kidneys and process for its manufacture | |
| DE69625254T2 (en) | COMPOSITIONS AND METHODS FOR PRESERVING LIVING TISSUES | |
| Gayton et al. | The location of chloride in single striated muscle fibers of the giant barnacle | |
| Feuvray et al. | Effect of short dimethylsulfoxide perfusions on ultrastructure of the isolated rat heart | |
| Haynes | The action of salts and non-electrolytes upon buffer solutions and amphoteric electrolytes and the relation of these effects to the permeability of the cell | |
| Ponder | The permeability of human red cells to cations after treatment with resorcinol, n-butyl alcohol, and similar lysins | |
| Seyama et al. | The effect of high sodium concentration on the action potential of the skate heart | |
| DE710410C (en) | Process for increasing the coagulability of animal blood | |
| Stanton | The selective absorption of potassium by animal cells: iii. the effect of hydrogen ion concentration upon the retention of potassium | |
| Scholander | Oxygen Dissociation Curves in Fish Blood1 |
| Date | Code | Title | Description |
|---|---|---|---|
| OGA | New person/name/address of the applicant | ||
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |